Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And …

6 days ago · Delcath System’s Q3 earnings stated they pulled in $11.2M in revenue, driven by $10M in U.S. HEPZATO sales and $1.2M from CHEMOSAT in Europe. This was a 44% …

CouponFollow Extension

44%
OFF

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And …

4 days from now

6 days ago · Delcath System’s Q3 earnings stated they pulled in $11.2M in revenue, driven by $10M in U.S. HEPZATO sales and $1.2M from CHEMOSAT in Europe. This was a 44% …

seekingalpha.com

85%
OFF

DCTH - Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And...

4 days from now

6 days ago · Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is …

marketwirenews.com

44%
OFF

Delcath Systems Revenue Surges 44% To $11.2M As HEPZATO …

4 days from now

Nov 8, 2024 · Delcath Systems (NASDAQ: DCTH) reported strong Q3 2024 results with total revenue of $11.2 million, up 44% from previous quarter.This includes $10.0 million from …

stocktitan.net

44%
OFF

Delcath Systems Inc (DCTH) Q3 2024 Earnings: Revenue Surpasses ...

4 days from now

The third quarter of 2024 saw Delcath Systems Inc (DCTH, Financial) achieve a 44% increase in revenue from the previous quarter, driven by $10.0 million in sales from the HEPZATO KIT™ …

gurufocus.com

$11
OFF

Delcath Systems Records U.S. Quarterly Revenue From …

4 days from now

Oct 17, 2024 · Delcath Systems reported preliminary third quarter revenue of $11.2 million, which included the recording of $10.0 million in U.S. revenue from the commercialization of …

rttnews.com

$11
OFF

Delcath Systems Records U.S. Quarterly Revenue From …

4 days from now

Oct 17, 2024 · (RTTNews) - Delcath Systems (DCTH) reported preliminary third quarter revenue of $11.2 million, which included the recording of $10.0 million in U.S. revenue from the …

businessinsider.com

$1.50
OFF

Delcath Systems (DCTH) Stock Price, News & Analysis - MarketBeat

4 days from now

3 days ago · Earnings Growth. Earnings for Delcath Systems are expected to grow in the coming year, from ($1.50) to ($1.07) per share. ... Delcath Systems: Q3 Earnings Reveal HEPZATO …

marketbeat.com

$10
OFF

Delcath Begins Platform Expansion With Two Phase 2 Trials

4 days from now

5 days ago · Delcath's Q3 sales hit $10 million, unlocking $25 million for Phase 2 trials. ... 2024 7:50 AM ET Delcath Systems, Inc. (DCTH) Stock IMCR, IDYA 17 Comments. ... HEPZATO …

seekingalpha.com

FAQs about Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And … Coupon?

How did Delcath Systems perform in Q3?

Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. ...

How did Delcath Systems perform in third-quarter earnings?

In its latest earnings report, Delcath Systems, Inc. announced a significant increase in third-quarter revenues, reaching $11.2 million, a 44% rise from the previous quarter. This growth is largely attributed to the strong performance of its HEPZATO KIT, which has seen increasing adoption in the U.S. ...

Will Delcath's Q3 earnings help accelerate hepzato's adoption?

Overall, I believe Delcath posted promising Q3 earnings that not only revealed solid growth but also a strong balance sheet to help them fund their strategic goals to help accelerate HEPZATO’s adoption. In addition, the company highlighted their efforts to add new cancer indications to HEPZATO’s résumé and help redefine liver cancer treatments. ...

How much revenue did Delcath Systems (DCTH) make in third quarter?

(RTTNews) - Delcath Systems (DCTH) reported preliminary third quarter revenue of $11.2 million, which included the recording of $10.0 million in U.S. revenue from the commercialization of HEPZATO KIT. ...

Who is Delcath Systems?

Here is a breakdown of the information Delcath Systems, Inc. presented to its investors. Delcath Systems, Inc. is an interventional oncology company specializing in treatments for liver cancers, using its proprietary HEPZATO KIT and CHEMOSAT delivery systems to provide targeted chemotherapy with minimized side effects. ...

How is Delcath Systems positioned for continued growth?

Looking ahead, Delcath Systems is positioned for continued growth, with plans to expand its development pipeline and capitalize on the increasing interest in its HEPZATO KIT for other cancer types. The strong financial performance and strategic advancements underscore the company’s potential trajectory towards profitability. ...